|
|
Blood, 15 August 2008, Vol. 112, No. 4, pp. 1461-1471.
Prepublished online as a Blood First Edition Paper on May 19, 2008; DOI 10.1182/blood-2008-02-139634.
Previous Article | Table of Contents | Next Article 
PHAGOCYTES
Neutrophil secretion products pave the way for inflammatory monocytes
Oliver Soehnlein1,
Alma Zernecke2,
Einar E. Eriksson1,
Antonio Gigliotti Rothfuchs3,
Christine T. Pham4,
Heiko Herwald5,
Kiril Bidzhekov2,
Martin E. Rottenberg6,
Christian Weber2, and
Lennart Lindbom1
1 Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden;
2 Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany;
3 Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD;
4 Department of Medicine, Washington University, St Louis, MO;
5 Department of Clinical Sciences, Lund University, Lund, Sweden; and
6 Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
The leukocyte response in inflammation is characterized by an initial recruitment of polymorphonuclear leukocytes (PMN) preceding a second wave of monocytes to the site of injury or infection. In the mouse, 2 populations of monocytes have been identified, Gr1–CCR2–CX3CR1hi resident monocytes and Gr1+CCR2+CX3CR1lo inflammatory monocytes. Here, intravital microscopy of the musculus cremaster and a subcutaneous air pouch model were used to investigate a possible link between PMN extravasation and the subsequent emigration of inflammatory monocytes in response to local stimulation with PAF. In mice that were made neutropenic by injection of a PMN-depleting antibody, the extravasation of inflammatory monocytes, but not resident monocytes, was markedly reduced compared with mice with intact white blood cell count but was restored by local treatment with secretion of activated PMN. Components of the PMN secretion were found to directly activate inflammatory monocytes and further examination revealed PMN-derived LL-37 and heparin-binding protein (HBP/CAP37/azurocidin) as primary mediators of the recruitment of inflammatory monocytes via activation of formyl-peptide receptors. These data show that LL-37 and HBP specifically stimulate mobilization of inflammatory monocytes. This cellular cross-talk functionally results in enhanced cytokine levels and increased bacterial clearance, thus boosting the early immune response.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Bergsson, E. P. Reeves, P. McNally, S. H. Chotirmall, C. M. Greene, P. Greally, P. Murphy, S. J. O'Neill, and N. G. McElvaney
LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline
J. Immunol.,
July 1, 2009;
183(1):
543 - 551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Di Gennaro, E. Kenne, M. Wan, O. Soehnlein, L. Lindbom, and J. Z. Haeggstrom
Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin)
FASEB J,
June 1, 2009;
23(6):
1750 - 1757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, Y. Jia, M. Pichavant, F. Loison, B. Sarraj, A. Kasorn, J. You, B. E. Robson, D. T. Umetsu, J. P. Mizgerd, et al.
Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia
Blood,
May 14, 2009;
113(20):
4930 - 4941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Koenen, J. Pruessmeyer, O. Soehnlein, L. Fraemohs, A. Zernecke, N. Schwarz, K. Reiss, A. Sarabi, L. Lindbom, T. M. Hackeng, et al.
Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases
Blood,
May 7, 2009;
113(19):
4799 - 4809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Soehnlein and L. Lindbom
Neutrophil-derived azurocidin alarms the immune system
J. Leukoc. Biol.,
March 1, 2009;
85(3):
344 - 351.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|